Drugs / OMX-0407
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05826600 | Mar 2023 → Apr 2026 | cancer | iOmx Therapeutics AG | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2025-05-30 | iOmx Therapeutics AG | Results OMX 0407 : A novel spectrum selective small molecule kinase inhibitor in advanced/metastatic solid tumors iomx.com ↗
Most patients discontinued due to progressive disease, 1 patient had a durable complete response (see below), and 1 patient had a stable disease (Fig. 4). |
| 2025-04-25 | iOmx Therapeutics AG | Results Pharmacodynamic biomarker modulation by OMX-0407, a novel, spectrum-selective kinase inhibitor for the treatment of angiosarcoma and renal cell carcinoma iomx.com ↗
One patient with secondary radiation-induced angiosarcoma achieved a complete response at doses of up to 60 mg BID, which remains ongoing at 19 months. |
| 2025-04-25 | iOmx Therapeutics AG | Results OMX-0407 – a spectrum selective kinase inhibitor shows preclinical efficacy in RCC as well as Sarcomas iomx.com ↗
In a patient-derived xenograft (PDX) model of human angiosarcoma (AS), OMX-0407 demonstrated dose-dependent efficacy, resulting in significant tumor inhibition. |
| 2024-11-14 | iOmx Therapeutics AG | Results OMX-0407 in Treatment of Angiosarcoma iomx.com ↗
OMX-0407 demonstrated dose-dependent efficacy in the PDX model, with significant tumor growth inhibition at both doses tested (25 mg/kg and 50 mg/kg), resulting also in intra-tumoral de-phosphorylation of SFKs. |
| 2024-08-22 | iOmx Therapeutics AG | Results iOmx Therapeutics Initiates Phase Ib with OMX-0407 iomx.com ↗ |
| 2024-04-17 | iOmx Therapeutics AG | Results OMX-0407 AACR 2024 iomx.com ↗
OMX-0407, a potent spectrum-selective kinase inhibitor demonstrates outstanding anti-tumor efficacy in vitro as well as ex vivo in a variety of cancer cell lines across different indications. |
| 2022-04-13 | iOmx Therapeutics AG | Results OMX-0407 Synergy with PD-1 iomx.com ↗
Using immune checkpoint inhibitor resistant breast (EMT6) and lung (KLN205) cancer models, we demonstrate that OMX-0407 and anti-PD-1 therapy act synergistically by combining the sensitization towards cell death with a reduction in immunosuppressive TME and an increase in cytotoxic T cell activity. |
| 2022-04-07 | iOmx Therapeutics AG | Results iOmx to Present Pre-Clinical Data on SIK3 at AACR 2022 iomx.com ↗ |
All press releases naming this drug 12 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OMX-0407 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05826600 ↗ |
| Action | Inhibit | “a Salt-inducible Kinase Inhibitor” NCT05826600 ↗ |
| Route | Oral | “A dose of 100 mg OMX-0407 will be orally administered twice daily.” NCT05826600 ↗ |